Joanne Wuensch
Stock Analyst at Citigroup
(4.48)
# 224
Out of 4,829 analysts
373
Total ratings
63.35%
Success rate
12.41%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Neutral | $14 → $13 | $11.27 | +15.35% | 5 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $105 → $86 | $69.87 | +23.09% | 4 | Apr 30, 2025 | |
| COO The Cooper Companies | Maintains: Buy | $115 → $110 | $82.26 | +33.72% | 20 | Mar 7, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $135 → $160 | $133.24 | +20.08% | 20 | Mar 4, 2025 | |
| DXCM DexCom | Maintains: Buy | $101 → $104 | $84.67 | +22.83% | 13 | Mar 4, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $4.6 → $3 | $3.08 | -2.60% | 10 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $35 → $24 | $22.98 | +4.44% | 14 | Mar 4, 2025 | |
| MDT Medtronic | Upgrades: Buy | $92 → $107 | $83.48 | +28.17% | 19 | Mar 4, 2025 | |
| SYK Stryker | Reinstates: Buy | $450 | $380.92 | +18.14% | 13 | Feb 26, 2025 | |
| PODD Insulet | Maintains: Buy | $310 → $355 | $310.67 | +14.27% | 14 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $122 | $102.86 | +18.61% | 34 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $640 → $711 | $536.51 | +32.52% | 16 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $200 → $245 | $297.32 | -17.60% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $185 → $175 | $154.22 | +13.47% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $145 | $118.44 | +22.42% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $83 | $73.68 | +12.65% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $30.90 | +13.27% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $3.37 | +122.55% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $89.96 | +80.08% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $12.25 | +79.59% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $33.92 | +47.41% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $137.70 | -20.12% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $68.19 | +24.65% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $95.21 | +26.04% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $167.22 | +49.50% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $95.75 | -27.94% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $245.04 | -48.17% | 6 | Dec 10, 2018 |
Bausch + Lomb
May 1, 2025
Maintains: Neutral
Price Target: $14 → $13
Current: $11.27
Upside: +15.35%
GE HealthCare Technologies
Apr 30, 2025
Maintains: Buy
Price Target: $105 → $86
Current: $69.87
Upside: +23.09%
The Cooper Companies
Mar 7, 2025
Maintains: Buy
Price Target: $115 → $110
Current: $82.26
Upside: +33.72%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $135 → $160
Current: $133.24
Upside: +20.08%
DexCom
Mar 4, 2025
Maintains: Buy
Price Target: $101 → $104
Current: $84.67
Upside: +22.83%
Sight Sciences
Mar 4, 2025
Maintains: Neutral
Price Target: $4.6 → $3
Current: $3.08
Upside: -2.60%
Tandem Diabetes Care
Mar 4, 2025
Downgrades: Neutral
Price Target: $35 → $24
Current: $22.98
Upside: +4.44%
Medtronic
Mar 4, 2025
Upgrades: Buy
Price Target: $92 → $107
Current: $83.48
Upside: +28.17%
Stryker
Feb 26, 2025
Reinstates: Buy
Price Target: $450
Current: $380.92
Upside: +18.14%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $310 → $355
Current: $310.67
Upside: +14.27%
Feb 6, 2025
Maintains: Buy
Price Target: $107 → $122
Current: $102.86
Upside: +18.61%
Jan 24, 2025
Maintains: Buy
Price Target: $640 → $711
Current: $536.51
Upside: +32.52%
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $297.32
Upside: -17.60%
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $154.22
Upside: +13.47%
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $118.44
Upside: +22.42%
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $73.68
Upside: +12.65%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $30.90
Upside: +13.27%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $3.37
Upside: +122.55%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $89.96
Upside: +80.08%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $12.25
Upside: +79.59%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $33.92
Upside: +47.41%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $137.70
Upside: -20.12%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $68.19
Upside: +24.65%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $95.21
Upside: +26.04%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $167.22
Upside: +49.50%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $95.75
Upside: -27.94%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $245.04
Upside: -48.17%